421 related articles for article (PubMed ID: 17626202)
1. Nuclear localization of ataxin-3 is required for the manifestation of symptoms in SCA3: in vivo evidence.
Bichelmeier U; Schmidt T; Hübener J; Boy J; Rüttiger L; Häbig K; Poths S; Bonin M; Knipper M; Schmidt WJ; Wilbertz J; Wolburg H; Laccone F; Riess O
J Neurosci; 2007 Jul; 27(28):7418-28. PubMed ID: 17626202
[TBL] [Abstract][Full Text] [Related]
2. A new humanized ataxin-3 knock-in mouse model combines the genetic features, pathogenesis of neurons and glia and late disease onset of SCA3/MJD.
Switonski PM; Szlachcic WJ; Krzyzosiak WJ; Figiel M
Neurobiol Dis; 2015 Jan; 73():174-88. PubMed ID: 25301414
[TBL] [Abstract][Full Text] [Related]
3. Polyglutamine-induced neurodegeneration in SCA3 is not mitigated by non-expanded ataxin-3: conclusions from double-transgenic mouse models.
Hübener J; Riess O
Neurobiol Dis; 2010 Apr; 38(1):116-24. PubMed ID: 20079840
[TBL] [Abstract][Full Text] [Related]
4. Spinocerebellar ataxia type 3 (SCA3): thalamic neurodegeneration occurs independently from thalamic ataxin-3 immunopositive neuronal intranuclear inclusions.
Rüb U; de Vos RA; Brunt ER; Sebestény T; Schöls L; Auburger G; Bohl J; Ghebremedhin E; Gierga K; Seidel K; den Dunnen W; Heinsen H; Paulson H; Deller T
Brain Pathol; 2006 Jul; 16(3):218-27. PubMed ID: 16911479
[TBL] [Abstract][Full Text] [Related]
5. Ataxin-3 protein modification as a treatment strategy for spinocerebellar ataxia type 3: removal of the CAG containing exon.
Evers MM; Tran HD; Zalachoras I; Pepers BA; Meijer OC; den Dunnen JT; van Ommen GJ; Aartsma-Rus A; van Roon-Mom WM
Neurobiol Dis; 2013 Oct; 58():49-56. PubMed ID: 23659897
[TBL] [Abstract][Full Text] [Related]
6. Ataxin-3 is translocated into the nucleus for the formation of intranuclear inclusions in normal and Machado-Joseph disease brains.
Fujigasaki H; Uchihara T; Koyano S; Iwabuchi K; Yagishita S; Makifuchi T; Nakamura A; Ishida K; Toru S; Hirai S; Ishikawa K; Tanabe T; Mizusawa H
Exp Neurol; 2000 Oct; 165(2):248-56. PubMed ID: 10993685
[TBL] [Abstract][Full Text] [Related]
7. Silencing mutant ataxin-3 rescues motor deficits and neuropathology in Machado-Joseph disease transgenic mice.
Nóbrega C; Nascimento-Ferreira I; Onofre I; Albuquerque D; Hirai H; Déglon N; de Almeida LP
PLoS One; 2013; 8(1):e52396. PubMed ID: 23349684
[TBL] [Abstract][Full Text] [Related]
8. Evidence for proteasome involvement in polyglutamine disease: localization to nuclear inclusions in SCA3/MJD and suppression of polyglutamine aggregation in vitro.
Chai Y; Koppenhafer SL; Shoesmith SJ; Perez MK; Paulson HL
Hum Mol Genet; 1999 Apr; 8(4):673-82. PubMed ID: 10072437
[TBL] [Abstract][Full Text] [Related]
9. Beclin 1 mitigates motor and neuropathological deficits in genetic mouse models of Machado-Joseph disease.
Nascimento-Ferreira I; Nóbrega C; Vasconcelos-Ferreira A; Onofre I; Albuquerque D; Aveleira C; Hirai H; Déglon N; Pereira de Almeida L
Brain; 2013 Jul; 136(Pt 7):2173-88. PubMed ID: 23801739
[TBL] [Abstract][Full Text] [Related]
10. Reversibility of symptoms in a conditional mouse model of spinocerebellar ataxia type 3.
Boy J; Schmidt T; Wolburg H; Mack A; Nuber S; Böttcher M; Schmitt I; Holzmann C; Zimmermann F; Servadio A; Riess O
Hum Mol Genet; 2009 Nov; 18(22):4282-95. PubMed ID: 19666958
[TBL] [Abstract][Full Text] [Related]
11. Calpain-mediated ataxin-3 cleavage in the molecular pathogenesis of spinocerebellar ataxia type 3 (SCA3).
Hübener J; Weber JJ; Richter C; Honold L; Weiss A; Murad F; Breuer P; Wüllner U; Bellstedt P; Paquet-Durand F; Takano J; Saido TC; Riess O; Nguyen HP
Hum Mol Genet; 2013 Feb; 22(3):508-18. PubMed ID: 23100324
[TBL] [Abstract][Full Text] [Related]
12. Polyglutamine-expanded ataxin-3 impairs long-term depression in Purkinje neurons of SCA3 transgenic mouse by inhibiting HAT and impairing histone acetylation.
Chou AH; Chen YL; Hu SH; Chang YM; Wang HL
Brain Res; 2014 Oct; 1583():220-9. PubMed ID: 25139423
[TBL] [Abstract][Full Text] [Related]
13. Involvement of Onuf's nucleus in Machado-Joseph disease: a morphometric and immunohistochemical study.
Shimizu H; Yamada M; Toyoshima Y; Ikeuchi T; Onodera O; Takahashi H
Acta Neuropathol; 2010 Oct; 120(4):439-48. PubMed ID: 20503052
[TBL] [Abstract][Full Text] [Related]
14. Motor uncoordination and neuropathology in a transgenic mouse model of Machado-Joseph disease lacking intranuclear inclusions and ataxin-3 cleavage products.
Silva-Fernandes A; Costa Mdo C; Duarte-Silva S; Oliveira P; Botelho CM; Martins L; Mariz JA; Ferreira T; Ribeiro F; Correia-Neves M; Costa C; Maciel P
Neurobiol Dis; 2010 Oct; 40(1):163-76. PubMed ID: 20510362
[TBL] [Abstract][Full Text] [Related]
15. Non-expanded polyglutamine proteins in intranuclear inclusions of hereditary ataxias--triple-labeling immunofluorescence study.
Uchihara T; Fujigasaki H; Koyano S; Nakamura A; Yagishita S; Iwabuchi K
Acta Neuropathol; 2001 Aug; 102(2):149-52. PubMed ID: 11563629
[TBL] [Abstract][Full Text] [Related]
16. Vulnerability of frontal brain neurons for the toxicity of expanded ataxin-3.
Schmidt J; Mayer AK; Bakula D; Freude J; Weber JJ; Weiss A; Riess O; Schmidt T
Hum Mol Genet; 2019 May; 28(9):1463-1473. PubMed ID: 30576445
[TBL] [Abstract][Full Text] [Related]
17. In vivo suppression of polyglutamine neurotoxicity by C-terminus of Hsp70-interacting protein (CHIP) supports an aggregation model of pathogenesis.
Williams AJ; Knutson TM; Colomer Gould VF; Paulson HL
Neurobiol Dis; 2009 Mar; 33(3):342-53. PubMed ID: 19084066
[TBL] [Abstract][Full Text] [Related]
18. A mutant ataxin-3 fragment results from processing at a site N-terminal to amino acid 190 in brain of Machado-Joseph disease-like transgenic mice.
Colomer Gould VF; Goti D; Pearce D; Gonzalez GA; Gao H; Bermudez de Leon M; Jenkins NA; Copeland NG; Ross CA; Brown DR
Neurobiol Dis; 2007 Sep; 27(3):362-9. PubMed ID: 17632007
[TBL] [Abstract][Full Text] [Related]
19. [Polyglutamine-expanded ataxin-3 is degraded by autophagy].
Xiao H; Tang J; Hu Z; Tan J; Tang B; Jiang Z
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2010 Feb; 27(1):23-8. PubMed ID: 20140862
[TBL] [Abstract][Full Text] [Related]
20. Progress in pathogenesis studies of spinocerebellar ataxia type 1.
Cummings CJ; Orr HT; Zoghbi HY
Philos Trans R Soc Lond B Biol Sci; 1999 Jun; 354(1386):1079-81. PubMed ID: 10434309
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
